These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9532703)
1. [The principles in correcting secondary immunodeficiencies by using 2 immunomodulators of differing character--purified staphylococcal anatoxin and likopid]. Semenova IB Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):100-4. PubMed ID: 9532703 [No Abstract] [Full Text] [Related]
2. [Immunomodulators of microbial origin enhance cytotoxicity of human mononuclear leukocytes and reduce metastatic progression of Lewis lung carcinoma in mice]. Akhmatova NK; Semenova IB; Donenko FV; Kiselevskiĭ MV; Kurbatova EA; Egorova NB Zh Mikrobiol Epidemiol Immunobiol; 2006; (6):35-40. PubMed ID: 17163136 [TBL] [Abstract][Full Text] [Related]
3. [Correction of immune response using purified staphylococcal toxoid and likopid in the secondary immunodeficiency induced by Coxsackie virus B3]. Semenova IB; Vasil'eva IG; Akatov AK Zh Mikrobiol Epidemiol Immunobiol; 2001; (5):42-5. PubMed ID: 11871300 [TBL] [Abstract][Full Text] [Related]
4. [Theoretical problems of use of an immunomodulator likopid in clinical practice]. Andronova TM; Chumakova MM Ter Arkh; 2002; 74(1):70-2. PubMed ID: 11878067 [No Abstract] [Full Text] [Related]
5. [Use of likopid--an immunomodulator in the combined treatment of patients with endometrial adenocarcinoma]. Venediktova MG; Rumiantseva NK; Fedorova GV; Demidova MA; Zhilenko MI Vopr Onkol; 2001; 47(4):481-4. PubMed ID: 11710296 [No Abstract] [Full Text] [Related]
6. [The characteristics of the action of a chemical immunomodulator in a latent viral infection]. Kalenderov AK; Semenova IB Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):87-8. PubMed ID: 8079590 [No Abstract] [Full Text] [Related]
7. [Comparative characteristic of the treatment efficacy in patients with often recurrent acute respiratory infections complicated with immunodeficiency treated with likopid]. Chop'iak VV; Pot'omkina HO Lik Sprava; 2013 Mar; (2):106-17. PubMed ID: 24605620 [TBL] [Abstract][Full Text] [Related]
8. [An immunomodifier--staphylococcal anatoxin--prevents the development of immunosuppression caused by informational stress in mice]. Ozherelkov SV; Semenova IB; Vagin VV; Nikol'skaia KA; Savanenko AV; Semenov BF Zh Mikrobiol Epidemiol Immunobiol; 1996; (4):71-4. PubMed ID: 9027182 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and immunologic effect of likopid in complex therapy of occupational bronchial asthma]. Tarasova OV Med Tr Prom Ekol; 2001; (11):31-4. PubMed ID: 11768952 [TBL] [Abstract][Full Text] [Related]
10. [The correction of a secondary immunological deficit caused by the Coxsackie B3 virus by using an immunomodulator of bacterial origin]. Semenova IB; Vasil'eva IG; Akatov AK Zh Mikrobiol Epidemiol Immunobiol; 1993; (6):83-4. PubMed ID: 8079587 [No Abstract] [Full Text] [Related]
11. [Current aspects of diagnosis and treatment of atopic diseases complicated by secondary immunodeficiency]. Mikheeva GN; Khaitov RM Ter Arkh; 1998; 70(4):54-60. PubMed ID: 9612905 [TBL] [Abstract][Full Text] [Related]
12. Approaches to cancer therapy using biological response modifiers. MacEwen EG Vet Clin North Am Small Anim Pract; 1985 May; 15(3):667-88. PubMed ID: 2409659 [No Abstract] [Full Text] [Related]
14. [ADTP vaccine induces temporary immunosuppression correctable by using the immunomodulator purified staphylococcal anatoxin]. Semenova IB; Akatov AK Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):78-9. PubMed ID: 7879556 [No Abstract] [Full Text] [Related]
15. [Clinico-immunological effectiveness of likopid in conservative treatment of patients with chronic tonsillitis and chronic sinusitis]. Filatova SV; Pinegin BV; Simonova AV; Artem'ev ME; Golubeva NM Vestn Otorinolaringol; 2001; (5):26-8. PubMed ID: 11699088 [TBL] [Abstract][Full Text] [Related]
16. [Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide]. Ushkalova EA; Zyryanov SK; Zatolochina KE Ter Arkh; 2019 Dec; 91(12):122-127. PubMed ID: 32598599 [TBL] [Abstract][Full Text] [Related]
17. [The effect on Coxsackie B3 viral infection of these different immunomodifiers: pertussis corpuscular vaccine, purified staphylococcal anatoxin and their combination]. Semenova IB; Akatov AK Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):54-5. PubMed ID: 8553757 [No Abstract] [Full Text] [Related]
18. Higher immunoadjuvant activities of N-acetyl-beta-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine in comparison with N-acetylmuramyl-L-alanyl-D-isoglutamine. Tsujimoto M; Kinoshita F; Okunaga T; Kotani S; Kusumoto S; Yamamoto K; Shiba T Microbiol Immunol; 1979; 23(9):933-6. PubMed ID: 576117 [No Abstract] [Full Text] [Related]
19. New approaches for control of infections using synthetic or semi-synthetic constructs containing MDP. Chedid L; Audibert F Springer Semin Immunopathol; 1985; 8(4):401-12. PubMed ID: 4089758 [No Abstract] [Full Text] [Related]
20. Immune boosters. Murabutide--debut of a new immune booster? TreatmentUpdate; 2003; 15(4):3. PubMed ID: 17216851 [No Abstract] [Full Text] [Related] [Next] [New Search]